文献速递浆细胞疾病

基于染色质信息的游离DNA方法检测多发性骨髓瘤可测量病灶

Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma.
PubMed 文献 · Blood Adv · 2026-10-06

本研究开发了MATADOR框架,利用固定多发性骨髓瘤特异性染色质可及调控区域的cfDNA片段化模式,无需患者个体化肿瘤 profiling,在留出测试集中区分临床可测量与不可测量疾病的AUROC为0.94,为MM提供微创血液评估方法。

要点

  • MATADOR基于固定染色质可及区域cfDNA片段化模式,无需个体化肿瘤 profiling。
  • 在留出测试集中区分可测量与不可测量疾病AUROC达0.94。
  • 染色质信息cfDNA片段组学可作为MM微创疾病评估手段。

核心结论

  • 染色质信息cfDNA片段组学可在无需个体化肿瘤 profiling 的情况下区分MM临床可测量与不可测量疾病。

研究设计与样本

  • 开发MATADOR框架,利用独立MM队列单核ATAC-seq数据定义固定染色质可及调控区域,在留出测试集中评估。

主要发现

  • 仅用位点特异性特征,MATADOR在留出测试集中区分临床可测量与不可测量疾病的AUROC为0.94。

关键数值与推荐

  • 区分临床可测量与不可测量疾病的AUROC为0.94(留出测试集)。

临床怎么用

  • 可提供基于血液的微创疾病评估,突破骨髓采样单一解剖位点限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is monitored using bone marrow-based minimal residual disease (MRD) assays, which provide high sensitivity but require repeated invasive sampling and are limited to a single anatomical site. Cell-free DNA (cfDNA) offers a minimally invasive alternative, yet most cfDNA approaches rely on prior tumor profiling to identify patient-specific genomic alterations for subsequent tracking in plasma. Here, we developed MATADOR, a myeloma-specific, tumor-agnostic framework that leverages cfDNA fragmentation patterns at a fixed set of myeloma-specific chromatin-accessible regulatory regions. These regions were defined using single-nucleus ATAC-seq data from an independent MM cohort and used to quantify plasma cfDNA fragmentation at these loci without patient-specific tumor profiling. Using these locus-specific features alone, MATADOR distinguished clinically measurable from unmeasurable disease in a held-out test set with an area under the receiver operating characteristic curve (AUROC) of 0.94. These findings establish chromatin-informed cfDNA fragmentomics as a minimally invasive approach for disease assessment in MM without individualized tumor profiling, enabling blood-based assessment of disease beyond the constraints of bone marrow sampling.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bajaj P, Abelman DD, Luo P, et al. Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma. Blood Adv. 2026. PMID: 42837666. doi:10.1182/bloodadvances.2026022335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。